
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
        <meta name="description" content="Diagnosis, treatment initiation, and long-term management of CIDP including IVIg, corticosteroids, plasma exchange, and immunosuppressive therapies.">
      
      
      
        <link rel="canonical" href="https://blondarb.github.io/neuro-plans/drafts/cidp/">
      
      
      
      
        
      
      
      <link rel="icon" href="../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.7.1">
    
    
      
        <title>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Neuro Clinical Plans</title>
      
    
    
      <link rel="stylesheet" href="../../assets/stylesheets/main.484c7ddc.min.css">
      
        
        <link rel="stylesheet" href="../../assets/stylesheets/palette.ab4e12ef.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../assets/css/custom.css">
    
    <script>__md_scope=new URL("../..",location),__md_hash=e=>[...e].reduce(((e,_)=>(e<<5)-e+_.charCodeAt(0)),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#chronic-inflammatory-demyelinating-polyneuropathy-cidp" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../.." title="Neuro Clinical Plans" class="md-header__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3zm0 5h18v2H3zm0 5h18v2H3z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Neuro Clinical Plans
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="default" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a4 4 0 0 0-4 4 4 4 0 0 0 4 4 4 4 0 0 0 4-4 4 4 0 0 0-4-4m0 10a6 6 0 0 1-6-6 6 6 0 0 1 6-6 6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="" data-md-color-scheme="slate" data-md-color-primary="indigo" data-md-color-accent="indigo"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 18c-.89 0-1.74-.2-2.5-.55C11.56 16.5 13 14.42 13 12s-1.44-4.5-3.5-5.45C10.26 6.2 11.11 6 12 6a6 6 0 0 1 6 6 6 6 0 0 1-6 6m8-9.31V4h-4.69L12 .69 8.69 4H4v4.69L.69 12 4 15.31V20h4.69L12 23.31 15.31 20H20v-4.69L23.31 12z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var palette=__md_get("__palette");if(palette&&palette.color){if("(prefers-color-scheme)"===palette.color.media){var media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']");palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent")}for(var[key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      
      
        <label class="md-header__button md-icon" for="__search">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        </label>
        <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.52 6.52 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12z"/></svg>
        </button>
      </nav>
      
        <div class="md-search__suggest" data-md-component="search-suggest"></div>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
      
    
    
      <div class="md-header__source">
        <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
      </div>
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../.." title="Neuro Clinical Plans" class="md-nav__button md-logo" aria-label="Neuro Clinical Plans" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54"/></svg>

    </a>
    Neuro Clinical Plans
  </label>
  
    <div class="md-nav__source">
      <a href="https://github.com/blondarb/neuro-plans" title="Go to repository" class="md-source" data-md-component="source">
  <div class="md-source__icon md-icon">
    
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
  </div>
  <div class="md-source__repository">
    blondarb/neuro-plans
  </div>
</a>
    </div>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../.." class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Home
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    <li class="md-nav__item">
      <a href="../../clinical/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Interactive Clinical Tool
  

    
  </span>
  
  

      </a>
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3" >
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    Clinical Plans
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Clinical Plans
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Overview
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_2" >
        
          
          <label class="md-nav__link" for="__nav_3_2" id="__nav_3_2_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Seizures & Epilepsy
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_2_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_2">
            <span class="md-nav__icon md-icon"></span>
            
  
    Seizures & Epilepsy
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/status-epilepticus/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Status Epilepticus
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/new-onset-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    New Onset Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/breakthrough-seizure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Breakthrough Seizure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_3" >
        
          
          <label class="md-nav__link" for="__nav_3_3" id="__nav_3_3_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Stroke & Vascular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_3">
            <span class="md-nav__icon md-icon"></span>
            
  
    Stroke & Vascular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/acute-ischemic-stroke/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Ischemic Stroke
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/transient-ischemic-attack/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Transient Ischemic Attack
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/intracerebral-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Intracerebral Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/subarachnoid-hemorrhage/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Subarachnoid Hemorrhage
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_4" >
        
          
          <label class="md-nav__link" for="__nav_3_4" id="__nav_3_4_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuromuscular
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/guillain-barre-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Guillain-Barr√© Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/myasthenia-gravis-crisis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenic Crisis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/myasthenia-gravis-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Myasthenia Gravis - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/neuromuscular-respiratory-failure/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Neuromuscular Respiratory Failure
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/peripheral-neuropathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Peripheral Neuropathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_5" >
        
          
          <label class="md-nav__link" for="__nav_3_5" id="__nav_3_5_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    CNS Infections
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_5_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_5">
            <span class="md-nav__icon md-icon"></span>
            
  
    CNS Infections
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/bacterial-meningitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bacterial Meningitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/hsv-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    HSV Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/autoimmune-encephalitis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Autoimmune Encephalitis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_6" >
        
          
          <label class="md-nav__link" for="__nav_3_6" id="__nav_3_6_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Spinal Emergencies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_6_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_6">
            <span class="md-nav__icon md-icon"></span>
            
  
    Spinal Emergencies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/acute-myelopathy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Acute Myelopathy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/spinal-cord-compression-malignant/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Spinal Cord Compression (Malignant)
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/cauda-equina-syndrome/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Cauda Equina Syndrome
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/epidural-abscess/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Epidural Abscess
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_7" >
        
          
          <label class="md-nav__link" for="__nav_3_7" id="__nav_3_7_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Neuro-Oncology
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_7_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_7">
            <span class="md-nav__icon md-icon"></span>
            
  
    Neuro-Oncology
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/brain-metastases/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Brain Metastases
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_8" >
        
          
          <label class="md-nav__link" for="__nav_3_8" id="__nav_3_8_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Critical Care
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_8_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_8">
            <span class="md-nav__icon md-icon"></span>
            
  
    Critical Care
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/elevated-icp-management/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Elevated ICP Management
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_9" >
        
          
          <label class="md-nav__link" for="__nav_3_9" id="__nav_3_9_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Demyelinating
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_9_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_9">
            <span class="md-nav__icon md-icon"></span>
            
  
    Demyelinating
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/ms-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    MS New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_10" >
        
          
          <label class="md-nav__link" for="__nav_3_10" id="__nav_3_10_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Headache
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_10_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_10">
            <span class="md-nav__icon md-icon"></span>
            
  
    Headache
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/migraine/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Migraine
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_11" >
        
          
          <label class="md-nav__link" for="__nav_3_11" id="__nav_3_11_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Movement Disorders
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_11_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_11">
            <span class="md-nav__icon md-icon"></span>
            
  
    Movement Disorders
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/parkinsons-disease-new-diagnosis/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Parkinson's Disease - New Diagnosis
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/essential-tremor/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Essential Tremor
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_12" >
        
          
          <label class="md-nav__link" for="__nav_3_12" id="__nav_3_12_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Dementia & Cognitive
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_12_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_12">
            <span class="md-nav__icon md-icon"></span>
            
  
    Dementia & Cognitive
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/dementia-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Dementia Evaluation
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/rapidly-progressive-dementia/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Rapidly Progressive Dementia
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_13" >
        
          
          <label class="md-nav__link" for="__nav_3_13" id="__nav_3_13_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Cranial Neuropathies
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_13_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_13">
            <span class="md-nav__icon md-icon"></span>
            
  
    Cranial Neuropathies
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/bells-palsy/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Bell's Palsy
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
              
                
  
  
  
  
    
    
    
    
      
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_3_14" >
        
          
          <label class="md-nav__link" for="__nav_3_14" id="__nav_3_14_label" tabindex="0">
            
  
  
  <span class="md-ellipsis">
    
  
    Other
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="2" aria-labelledby="__nav_3_14_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3_14">
            <span class="md-nav__icon md-icon"></span>
            
  
    Other
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../plans/vertigo-dizziness-evaluation/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Vertigo / Dizziness
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
      
        
        
      
    
    
    <li class="md-nav__item md-nav__item--section md-nav__item--nested">
      
        
        
          
        
        <input class="md-nav__toggle md-toggle md-toggle--indeterminate" type="checkbox" id="__nav_4" >
        
          
          <label class="md-nav__link" for="__nav_4" id="__nav_4_label" tabindex="">
            
  
  
  <span class="md-ellipsis">
    
  
    References
  

    
  </span>
  
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_4_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_4">
            <span class="md-nav__icon md-icon"></span>
            
  
    References
  

          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/lp-reference/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    LP Reference
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
              
                
  
  
  
  
    <li class="md-nav__item">
      <a href="../../references/tracker/" class="md-nav__link">
        
  
  
  <span class="md-ellipsis">
    
  
    Template Tracker
  

    
  </span>
  
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#1-laboratory-workup" class="md-nav__link">
    <span class="md-ellipsis">
      
        1. LABORATORY WORKUP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#2-diagnostic-imaging-studies" class="md-nav__link">
    <span class="md-ellipsis">
      
        2. DIAGNOSTIC IMAGING &amp; STUDIES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#3-treatment" class="md-nav__link">
    <span class="md-ellipsis">
      
        3. TREATMENT
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#4-other-recommendations" class="md-nav__link">
    <span class="md-ellipsis">
      
        4. OTHER RECOMMENDATIONS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#5-differential-diagnosis" class="md-nav__link">
    <span class="md-ellipsis">
      
        5. DIFFERENTIAL DIAGNOSIS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#6-monitoring-parameters" class="md-nav__link">
    <span class="md-ellipsis">
      
        6. MONITORING PARAMETERS
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#7-disposition-criteria" class="md-nav__link">
    <span class="md-ellipsis">
      
        7. DISPOSITION CRITERIA
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#8-evidence-references" class="md-nav__link">
    <span class="md-ellipsis">
      
        8. EVIDENCE &amp; REFERENCES
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#change-log" class="md-nav__link">
    <span class="md-ellipsis">
      
        CHANGE LOG
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-a-efnspns-2021-diagnostic-criteria-for-cidp" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX A: EFNS/PNS 2021 Diagnostic Criteria for CIDP
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-b-incat-disability-scale" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX B: INCAT Disability Scale
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-c-ivig-to-scig-conversion-guide" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX C: IVIg to SCIg Conversion Guide
      
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#appendix-d-monitoring-timeline" class="md-nav__link">
    <span class="md-ellipsis">
      
        APPENDIX D: Monitoring Timeline
      
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
            <div class="md-content" data-md-component="content">
              
              <article class="md-content__inner md-typeset">
                
                  

  <nav class="md-tags" >
    
      
      
      
      
        <a href="../../tags/#tag:autoimmune" class="md-tag">autoimmune</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:neuromuscular" class="md-tag">neuromuscular</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:neuropathy" class="md-tag">neuropathy</a>
      
    
      
      
      
      
        <a href="../../tags/#tag:outpatient" class="md-tag">outpatient</a>
      
    
  </nav>


  
  


<div class="draft-warning-banner">
  <div class="icon">‚ö†Ô∏è</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

<h1 id="chronic-inflammatory-demyelinating-polyneuropathy-cidp">Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)<a class="headerlink" href="#chronic-inflammatory-demyelinating-polyneuropathy-cidp" title="Permanent link">&para;</a></h1>
<p><strong>VERSION:</strong> 1.0
<strong>CREATED:</strong> January 27, 2026
<strong>REVISED:</strong> January 27, 2026
<strong>STATUS:</strong> Draft - Pending Review</p>
<hr />
<p><strong>DIAGNOSIS:</strong> Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</p>
<p><strong>ICD-10:</strong> G61.81</p>
<p><strong>SCOPE:</strong> Evaluation, diagnosis, treatment initiation, and long-term management of CIDP in adults. Covers typical CIDP, CIDP variants (MADSAM, DADS, sensory CIDP), first-line immunotherapy (IVIg, corticosteroids, plasmapheresis), second-line immunosuppressants, and subcutaneous immunoglobulin therapy. Primary focus is outpatient management with coverage for acute presentations and hospitalizations. Excludes Guillain-Barr√© syndrome (acute onset &lt;8 weeks), hereditary neuropathies (CMT), and pediatric CIDP.</p>
<p><strong>CLINICAL SYNONYMS:</strong> Chronic inflammatory demyelinating polyradiculoneuropathy, chronic relapsing polyneuropathy, chronic acquired demyelinating polyneuropathy, CIDP</p>
<p><strong>ADDITIONAL ICD-10 CODES:</strong>
- G61.89 - Other inflammatory polyneuropathies
- G62.9 - Polyneuropathy, unspecified (pre-diagnosis)</p>
<hr />
<p><strong>KEY CLINICAL FEATURES:</strong>
- Progressive or relapsing symmetric proximal AND distal weakness
- Sensory symptoms (numbness, paresthesias, sensory ataxia)
- Hyporeflexia or areflexia
- Duration &gt;8 weeks (distinguishes from GBS)
- Elevated CSF protein with normal cell count (albuminocytologic dissociation)
- Electrodiagnostic evidence of demyelination</p>
<p><strong>CIDP VARIANTS:</strong>
| Variant | Features | Notes |
|---------|----------|-------|
| Typical CIDP | Symmetric proximal and distal weakness, sensory loss | Most common (~50%) |
| MADSAM (Lewis-Sumner) | Multifocal, asymmetric; sensorimotor | May mimic MMN |
| DADS | Distal acquired demyelinating symmetric; sensory predominant | Often anti-MAG positive |
| Sensory CIDP | Pure sensory; ataxia, large fiber loss | NCS shows demyelination |
| Motor CIDP | Pure motor; no sensory involvement | Rare; consider MMN |
| Focal CIDP | Involvement of one or two limbs | Rare |</p>
<hr />
<p><strong>EFNS/PNS DIAGNOSTIC CRITERIA (2021 Update):</strong></p>
<p><strong>Clinical Criteria:</strong>
- Typical CIDP: Progressive or relapsing symmetric proximal and distal weakness AND sensory dysfunction of all extremities, developing over ‚â•8 weeks
- Cranial nerves may be affected
- Tendon reflexes reduced or absent in all limbs</p>
<p><strong>Supportive Criteria:</strong>
- CSF protein elevated with WBC &lt;10/mm¬≥
- MRI showing nerve root or plexus enhancement or hypertrophy
- Objective clinical improvement following immunomodulatory treatment</p>
<hr />
<p><strong>PRIORITY KEY:</strong> STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting</p>
<hr />
<div class="admonition info">
<p class="admonition-title">üìã CHRONIC DISEASE NOTE</p>
<p>CIDP is a chronic, treatable condition. Most patients respond to first-line immunotherapy. The goal is symptom control with minimal treatment burden. Long-term monitoring and periodic treatment adjustments are essential.</p>
</div>
<hr />
<p>‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
SECTION A: ACTION ITEMS
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê</p>
<h2 id="1-laboratory-workup">1. LABORATORY WORKUP<a class="headerlink" href="#1-laboratory-workup" title="Permanent link">&para;</a></h2>
<h3 id="1a-essentialcore-labs">1A. Essential/Core Labs<a class="headerlink" href="#1a-essentialcore-labs" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC with differential</td>
<td>Baseline, infection screen, pre-treatment</td>
<td>Normal</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>CMP (BMP + LFTs)</td>
<td>Electrolytes, renal/hepatic function for IVIg</td>
<td>Normal</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>ESR</td>
<td>Inflammatory marker; elevated in some CIDP</td>
<td>Document baseline</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>CRP</td>
<td>Inflammatory marker</td>
<td>Document baseline</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Diabetic neuropathy in differential; diabetes worsens CIDP</td>
<td>&lt;5.7% (normal); &gt;6.5% diagnostic for diabetes</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>Diabetes screening</td>
<td>&lt;100 mg/dL</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>TSH</td>
<td>Thyroid disease causing neuropathy</td>
<td>Normal (0.4-4.0 mIU/L)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>B12 deficiency neuropathy</td>
<td>&gt;300 pg/mL</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Methylmalonic acid</td>
<td>If B12 borderline (200-400 pg/mL)</td>
<td>Normal if B12 sufficient</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Serum protein electrophoresis (SPEP)</td>
<td>Paraproteinemic neuropathy screen</td>
<td>No monoclonal spike</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Serum immunofixation</td>
<td>Confirms monoclonal protein if SPEP abnormal</td>
<td>Characterize M-protein</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>HIV antibody</td>
<td>HIV-associated neuropathy/CIDP</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Hepatitis B surface antigen</td>
<td>Pre-IVIg screening; HBV reactivation risk</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Hepatitis B core antibody</td>
<td>Prior HBV exposure; reactivation risk with immunosuppression</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Hepatitis C antibody</td>
<td>HCV-associated cryoglobulinemic neuropathy</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<h3 id="1b-extended-workup-second-line">1B. Extended Workup (Second-line)<a class="headerlink" href="#1b-extended-workup-second-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine protein electrophoresis (UPEP)</td>
<td>Light chain deposition in neuropathy</td>
<td>No monoclonal protein</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Serum free light chains</td>
<td>AL amyloidosis, POEMS screening</td>
<td>Normal kappa:lambda ratio</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>VEGF level</td>
<td>Elevated in POEMS syndrome</td>
<td>Normal (&lt;200 pg/mL)</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Anti-MAG antibody</td>
<td>DADS variant; IgM paraproteinemic neuropathy</td>
<td>Negative (if positive, suggests DADS-CIDP or anti-MAG neuropathy)</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Anti-ganglioside antibodies (GM1, GD1a, GD1b)</td>
<td>MMN differentiation; axonal GBS variants</td>
<td>Document if positive</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Anti-GQ1b antibody</td>
<td>Miller Fisher variant if ophthalmoplegia</td>
<td>Document if positive</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Quantitative immunoglobulins (IgG, IgA, IgM)</td>
<td>IgA deficiency (IVIg contraindication); IgM elevation</td>
<td>IgA &gt;7 mg/dL; document IgM</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>ANA</td>
<td>Connective tissue disease screen</td>
<td>Negative or low titer</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Rheumatoid factor</td>
<td>Vasculitic neuropathy screen</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Anti-SSA/SSB</td>
<td>Sjogren syndrome neuropathy</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>ACE level</td>
<td>Sarcoid neuropathy</td>
<td>Normal</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>PT/INR, PTT</td>
<td>Pre-LP, pre-PLEX</td>
<td>Normal</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Type and screen</td>
<td>Pre-PLEX</td>
<td>Available</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">STAT</td>
</tr>
</tbody>
</table>
<h3 id="1c-rarespecialized-refractory-or-atypical">1C. Rare/Specialized (Refractory or Atypical)<a class="headerlink" href="#1c-rarespecialized-refractory-or-atypical" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Test</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-contactin-1 (CNTN1) antibody</td>
<td>Aggressive CIDP variant; poor IVIg response</td>
<td>Document if positive</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Anti-neurofascin-155 (NF155) antibody</td>
<td>Young onset, tremor, poor IVIg response</td>
<td>Document if positive</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Anti-caspr-1 antibody</td>
<td>Nodopathy; aggressive course</td>
<td>Document if positive</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Anti-NF186/NF140 antibodies</td>
<td>Nodal/paranodal antibodies</td>
<td>Document if positive</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Genetic testing for CMT</td>
<td>If family history or atypical features</td>
<td>Negative (excludes CMT)</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Lyme serology</td>
<td>Endemic area, outdoor exposure</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Heavy metals (lead, arsenic)</td>
<td>Toxic neuropathy differential</td>
<td>Normal</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Urine porphyrins</td>
<td>Motor neuropathy with systemic symptoms</td>
<td>Normal</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Bone marrow biopsy</td>
<td>If POEMS or amyloidosis suspected</td>
<td>Normal or diagnostic</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Fat pad biopsy for amyloid</td>
<td>If amyloidosis suspected</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Cryoglobulins</td>
<td>If HCV positive or vasculitic features</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="2-diagnostic-imaging-studies">2. DIAGNOSTIC IMAGING &amp; STUDIES<a class="headerlink" href="#2-diagnostic-imaging-studies" title="Permanent link">&para;</a></h2>
<h3 id="2a-essentialfirst-line">2A. Essential/First-line<a class="headerlink" href="#2a-essentialfirst-line" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nerve conduction studies (NCS)</td>
<td>At diagnosis; before treatment</td>
<td>Demyelinating features: prolonged distal latencies (&gt;125% ULN), slow conduction velocities (&lt;80% LLN), conduction block, temporal dispersion, prolonged F-waves</td>
<td>None</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Electromyography (EMG)</td>
<td>At diagnosis; with NCS</td>
<td>Secondary axonal loss; fibrillations in severe cases</td>
<td>Severe coagulopathy</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>Pre-treatment baseline</td>
<td>Normal (rule out mass if paraneoplastic concern)</td>
<td>None</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
</tbody>
</table>
<h3 id="2b-extended">2B. Extended<a class="headerlink" href="#2b-extended" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI spine with contrast (cervical/lumbar)</td>
<td>Diagnostic workup</td>
<td>Nerve root enhancement, cauda equina hypertrophy</td>
<td>Pacemaker, severe claustrophobia</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>MRI brachial plexus with contrast</td>
<td>If asymmetric or plexus involvement</td>
<td>Nerve hypertrophy, enhancement</td>
<td>Pacemaker</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>MRI lumbosacral plexus with contrast</td>
<td>If lower extremity predominant</td>
<td>Plexus enhancement, thickening</td>
<td>Pacemaker</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Nerve ultrasound</td>
<td>Complementary to MRI; assess nerve enlargement</td>
<td>Increased cross-sectional area of peripheral nerves</td>
<td>None</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>CT chest/abdomen/pelvis</td>
<td>If POEMS or malignancy suspected</td>
<td>Sclerotic bone lesions (POEMS), organomegaly</td>
<td>Contrast allergy, renal impairment</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<h3 id="2c-rarespecialized">2C. Rare/Specialized<a class="headerlink" href="#2c-rarespecialized" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Study</th>
<th>Timing</th>
<th>Target Finding</th>
<th>Contraindications</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET-CT</td>
<td>Occult malignancy, lymphoma, Castleman disease</td>
<td>Tumor identification</td>
<td>Hemodynamic instability</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Nerve biopsy (sural)</td>
<td>Diagnostic uncertainty, vasculitis suspected</td>
<td>Demyelination, inflammation, onion bulbs</td>
<td>Active infection at site</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Skeletal survey</td>
<td>POEMS evaluation</td>
<td>Sclerotic or lytic lesions</td>
<td>None</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<h3 id="lumbar-puncture">LUMBAR PUNCTURE<a class="headerlink" href="#lumbar-puncture" title="Permanent link">&para;</a></h3>
<p><strong>Indication:</strong> Confirm diagnosis (albuminocytologic dissociation); exclude infection or malignancy; required for EFNS/PNS supportive criteria</p>
<p><strong>Timing:</strong> ROUTINE for diagnosis; not urgent unless acute deterioration or infection concern</p>
<p><strong>Volume Required:</strong> 10-15 mL standard diagnostic</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Rationale</th>
<th>Target Finding</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening pressure</td>
<td>Baseline; usually normal in CIDP</td>
<td>10-20 cmH2O</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Cell count (tubes 1 and 4)</td>
<td>Albuminocytologic dissociation</td>
<td>WBC &lt;10/mm¬≥ (usually &lt;5)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Protein</td>
<td>Elevated in CIDP</td>
<td>Elevated (&gt;45 mg/dL; often 50-200 mg/dL)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Glucose</td>
<td>Exclude infection</td>
<td>Normal (&gt;60% serum glucose)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Gram stain and culture</td>
<td>Exclude infection</td>
<td>Negative</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Cytology</td>
<td>Exclude carcinomatous meningitis</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>VDRL</td>
<td>Neurosyphilis in differential</td>
<td>Negative</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Oligoclonal bands</td>
<td>MS or CNS inflammation in differential</td>
<td>Usually negative; may be mildly positive</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<p><strong>Special Handling:</strong> Cell count within 1 hour. Cytology refrigerated.</p>
<p><strong>Contraindications:</strong> Coagulopathy (INR &gt;1.5, platelets &lt;50K), anticoagulation, skin infection at LP site.</p>
<p><strong>NOTE:</strong> CSF protein is elevated in &gt;80% of CIDP patients. Normal CSF protein does not exclude CIDP if electrodiagnostic criteria are met.</p>
<hr />
<h2 id="3-treatment">3. TREATMENT<a class="headerlink" href="#3-treatment" title="Permanent link">&para;</a></h2>
<p><strong>CRITICAL:</strong> CIDP is treatable. First-line therapies (IVIg, corticosteroids, PLEX) are effective in ~80% of patients. Treatment choice depends on patient characteristics, access, and preference.</p>
<h3 id="treatment-selection-guidance">Treatment Selection Guidance<a class="headerlink" href="#treatment-selection-guidance" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Factor</th>
<th>IVIg Preferred</th>
<th>Corticosteroids Preferred</th>
<th>PLEX Preferred</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pure motor CIDP</strong></td>
<td>Yes</td>
<td>Avoid (may worsen motor)</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Diabetes mellitus</strong></td>
<td>Yes</td>
<td>Avoid (worsens glycemic control)</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Cost/access concerns</strong></td>
<td>If covered</td>
<td>Yes (low cost)</td>
<td>Limited access</td>
</tr>
<tr>
<td><strong>Rapid response needed</strong></td>
<td>Yes</td>
<td>No (slow onset)</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Long-term therapy</strong></td>
<td>Maintenance possible</td>
<td>Taper to lowest dose; add steroid-sparing</td>
<td>Not practical</td>
</tr>
<tr>
<td><strong>Pregnancy</strong></td>
<td>Preferred</td>
<td>Avoid if possible</td>
<td>Safe</td>
</tr>
<tr>
<td><strong>Nodal/paranodal antibodies</strong></td>
<td>May be less effective</td>
<td>May be effective</td>
<td>May be effective; rituximab preferred</td>
</tr>
</tbody>
</table>
<h3 id="3a-first-line-immunotherapy-induction">3A. First-line Immunotherapy - Induction<a class="headerlink" href="#3a-first-line-immunotherapy-induction" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVIg (immune globulin IV) - Loading</td>
<td>IV</td>
<td>First-line induction</td>
<td>2 g/kg over 2-5 days :: IV :: divided over 2-5 days :: 2 g/kg total divided over 2-5 days (e.g., 0.4 g/kg/day x 5 days or 1 g/kg/day x 2 days); infuse slowly day 1 (start 0.5-1 mL/kg/hr, max 4 mL/kg/hr)</td>
<td>IgA deficiency with anti-IgA antibodies; uncontrolled heart failure; recent thrombosis; severe renal impairment</td>
<td>Renal function, headache, infusion reactions; pre-medicate with acetaminophen and diphenhydramine</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Prednisone - Daily</td>
<td>PO</td>
<td>First-line induction (if IVIg unavailable or contraindicated)</td>
<td>60 mg daily; 1 mg/kg daily :: PO :: daily :: Start 60 mg (or 1 mg/kg) daily for 4-8 weeks until clinical improvement, then begin slow taper</td>
<td>Uncontrolled diabetes, active infection, psychosis, osteoporosis</td>
<td>Glucose, BP, bone density, mood, infection signs</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Prednisone - Pulse</td>
<td>PO</td>
<td>Alternative oral pulse therapy</td>
<td>40 mg daily x 5 days monthly :: PO :: daily x 5 days q4wk :: 40-60 mg daily for 5 consecutive days each month; may have fewer side effects than daily</td>
<td>Uncontrolled diabetes, active infection</td>
<td>Glucose, BP during pulse</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Methylprednisolone - IV Pulse</td>
<td>IV</td>
<td>Severe CIDP, rapid induction needed</td>
<td>1000 mg daily x 3-5 days :: IV :: daily x 3-5 days :: 1000 mg IV daily for 3-5 days; can repeat monthly as needed; transition to oral</td>
<td>Active untreated infection, uncontrolled HTN/diabetes</td>
<td>Glucose, BP, K+, psychiatric effects</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">URGENT</td>
</tr>
<tr>
<td>Plasma exchange (PLEX)</td>
<td>‚Äî</td>
<td>First-line if IVIg/steroids contraindicated or failed</td>
<td>5-10 exchanges over 2-4 weeks :: ‚Äî :: 2-3x/week :: 5-10 exchanges (1-1.5 plasma volumes each) over 2-4 weeks; typically 2-3 sessions per week</td>
<td>Hemodynamic instability, severe sepsis, poor vascular access</td>
<td>BP, electrolytes, coagulation, fibrinogen</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
</tr>
</tbody>
</table>
<h3 id="3b-first-line-immunotherapy-maintenance">3B. First-line Immunotherapy - Maintenance<a class="headerlink" href="#3b-first-line-immunotherapy-maintenance" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVIg - Maintenance</td>
<td>IV</td>
<td>Maintenance after loading response</td>
<td>0.4 g/kg q3wk; 0.5 g/kg q3wk; 1 g/kg q3-4wk :: IV :: q3-4wk :: 0.4-1 g/kg every 3-4 weeks; titrate to lowest effective dose and longest interval; some patients need 1 g/kg q2-3wk</td>
<td>IgA deficiency, renal impairment, recent thrombosis</td>
<td>Renal function q3-6mo; trough IgG levels optional</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>SCIg (Hizentra) - Maintenance</td>
<td>SC</td>
<td>Home maintenance after IVIg response</td>
<td>Weekly dose = IVIg monthly dose √∑ 4 :: SC :: weekly or divided :: Convert from IVIg: weekly SC dose equals monthly IV dose divided by 4; typical range 0.2-0.4 g/kg/week; divide into 1-7 infusions/week</td>
<td>Severe thrombocytopenia, skin conditions at injection site</td>
<td>Local site reactions; IgG trough levels q6mo</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>SCIg (Gamunex-C 10%) - Maintenance</td>
<td>SC</td>
<td>Home maintenance alternative</td>
<td>Weekly dose = IVIg monthly dose √∑ 4 :: SC :: weekly :: Same as Hizentra; 10% concentration; can give larger volume per site</td>
<td>Severe thrombocytopenia</td>
<td>Local reactions, IgG levels</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Prednisone - Maintenance taper</td>
<td>PO</td>
<td>Continuation after steroid induction</td>
<td>Taper by 5-10 mg q2-4wk :: PO :: daily :: After improvement, taper by 5-10 mg every 2-4 weeks; target lowest effective dose (often 5-20 mg daily or QOD); add steroid-sparing agent if unable to taper below 15-20 mg</td>
<td>Ongoing infection</td>
<td>Glucose, BP, bone density, cataracts</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<h3 id="3c-second-linesteroid-sparing-agents">3C. Second-line/Steroid-Sparing Agents<a class="headerlink" href="#3c-second-linesteroid-sparing-agents" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azathioprine</td>
<td>PO</td>
<td>Steroid-sparing; maintenance</td>
<td>50 mg daily; 100 mg daily; 150 mg daily; 2-3 mg/kg daily :: PO :: daily :: Start 50 mg daily; increase by 50 mg every 2-4 weeks to target 2-3 mg/kg/day; check TPMT before starting; onset 3-6 months</td>
<td>TPMT deficiency, pregnancy, myelosuppression</td>
<td>CBC weekly x 4 weeks, then monthly x 3 months, then q3mo; LFTs monthly</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>PO</td>
<td>Steroid-sparing; maintenance</td>
<td>500 mg BID; 1000 mg BID; 1500 mg BID :: PO :: BID :: Start 500 mg BID; increase to 1000-1500 mg BID over 2-4 weeks; onset 2-4 months</td>
<td>Pregnancy (teratogenic), severe renal impairment</td>
<td>CBC q2wk x 2 months, then monthly; LFTs</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Rituximab</td>
<td>IV</td>
<td>Refractory CIDP, nodal antibody-positive</td>
<td>375 mg/m¬≤ weekly x 4 weeks; 1000 mg q2wk x 2 :: IV :: weekly x 4 or q2wk x 2 :: 375 mg/m¬≤ weekly x 4 doses OR 1000 mg x 2 doses (2 weeks apart); repeat q6-12mo PRN; pre-medicate</td>
<td>Active infection, HBV (screen first; may reactivate)</td>
<td>Infusion reactions, CD19/CD20 counts, immunoglobulins; HBV DNA if prior exposure</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>IV</td>
<td>Severe refractory CIDP</td>
<td>1 g/m¬≤ monthly x 6 months :: IV :: monthly :: 1 g/m¬≤ IV monthly for 6 months; reserve for severe refractory cases</td>
<td>Pregnancy, active infection, hemorrhagic cystitis</td>
<td>CBC, urinalysis, fertility counseling; MESNA for bladder protection</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>PO</td>
<td>Steroid-sparing alternative</td>
<td>2.5-5 mg/kg/day divided BID :: PO :: BID :: Start 2.5 mg/kg/day divided BID; increase to 5 mg/kg/day based on levels and response; target trough 100-200 ng/mL</td>
<td>Uncontrolled HTN, renal impairment</td>
<td>Cr, BP, drug levels, K+, Mg</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<h3 id="3d-disease-modifying-therapy-special-populations">3D. Disease-Modifying Therapy - Special Populations<a class="headerlink" href="#3d-disease-modifying-therapy-special-populations" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Pre-Treatment Requirements</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVIg - Anti-MAG positive</td>
<td>IV</td>
<td>Anti-MAG neuropathy (may have partial response)</td>
<td>2 g/kg loading then 0.4-1 g/kg q3-4wk :: IV :: per protocol :: Anti-MAG neuropathy often less responsive to IVIg; may require rituximab if poor response</td>
<td>SPEP/UPEP to assess for underlying plasma cell dyscrasia</td>
<td>IgA deficiency</td>
<td>Response may be slower; consider rituximab if no improvement</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Rituximab - Anti-MAG positive</td>
<td>IV</td>
<td>Anti-MAG neuropathy preferred therapy</td>
<td>375 mg/m¬≤ weekly x 4 weeks; 1000 mg q2wk x 2 :: IV :: weekly x 4 or q2wk x 2 :: First-line for anti-MAG neuropathy given superior efficacy; repeat q6-12mo</td>
<td>HBV/HCV screening, quantitative immunoglobulins, CBC</td>
<td>Active HBV, active infection</td>
<td>Anti-MAG titers, CD19/20, immunoglobulins</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Rituximab - Nodal antibody positive (NF155, CNTN1)</td>
<td>IV</td>
<td>CIDP with nodal/paranodal antibodies</td>
<td>375 mg/m¬≤ weekly x 4 weeks; 1000 mg q2wk x 2 :: IV :: weekly x 4 or q2wk x 2 :: Preferred for NF155/CNTN1/CASPR1 positive CIDP (poor IVIg response); repeat q6mo</td>
<td>HBV/HCV screening, immunoglobulins</td>
<td>Active HBV</td>
<td>Antibody titers, B-cell counts</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<h3 id="3e-symptomatic-treatments">3E. Symptomatic Treatments<a class="headerlink" href="#3e-symptomatic-treatments" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabapentin</td>
<td>PO</td>
<td>Neuropathic pain</td>
<td>300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID :: PO :: TID :: Start 300 mg qHS; titrate by 300 mg/day q3d; target 900-1800 mg TID; max 3600 mg/day</td>
<td>Severe renal impairment (adjust dose)</td>
<td>Sedation, dizziness, edema; reduce dose if CrCl &lt;60</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>PO</td>
<td>Neuropathic pain</td>
<td>75 mg BID; 150 mg BID; 300 mg BID :: PO :: BID :: Start 75 mg BID; increase to 150 mg BID after 1 week; max 600 mg/day</td>
<td>Severe renal impairment (adjust dose)</td>
<td>Sedation, edema, weight gain</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>PO</td>
<td>Neuropathic pain, depression</td>
<td>30 mg daily; 60 mg daily :: PO :: daily :: Start 30 mg daily; increase to 60 mg daily after 1-2 weeks; max 120 mg/day</td>
<td>Uncontrolled glaucoma, severe hepatic impairment, MAOIs</td>
<td>BP, hepatic function, serotonin syndrome</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>PO</td>
<td>Neuropathic pain, sleep</td>
<td>10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: qHS :: Start 10 mg qHS; titrate by 10-25 mg q1-2wk; max 150 mg qHS</td>
<td>Cardiac arrhythmias, recent MI, glaucoma, urinary retention</td>
<td>ECG if &gt;100 mg/day; anticholinergic effects</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>PO</td>
<td>Mild pain</td>
<td>650 mg q6h PRN; 1000 mg q6h PRN :: PO :: q6h PRN :: 650-1000 mg q6h PRN; max 4 g/day (3 g if hepatic impairment)</td>
<td>Severe hepatic impairment</td>
<td>LFTs if prolonged use</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Mexiletine</td>
<td>PO</td>
<td>Muscle cramps, neuropathic pain (refractory)</td>
<td>150 mg TID; 200 mg TID :: PO :: TID :: Start 150 mg TID; may increase to 200-300 mg TID; max 1200 mg/day</td>
<td>Cardiac arrhythmia, heart block</td>
<td>ECG, hepatic function</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Baclofen</td>
<td>PO</td>
<td>Muscle cramps, spasms</td>
<td>5 mg TID; 10 mg TID; 20 mg TID :: PO :: TID :: Start 5 mg TID; increase by 5 mg/dose every 3 days; max 80 mg/day</td>
<td>Severe renal impairment</td>
<td>Sedation; do not stop abruptly</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<h3 id="3f-prophylaxis-and-supportive-care">3F. Prophylaxis and Supportive Care<a class="headerlink" href="#3f-prophylaxis-and-supportive-care" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Route</th>
<th>Indication</th>
<th>Dosing</th>
<th>Contraindications</th>
<th>Monitoring</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium + Vitamin D</td>
<td>PO</td>
<td>Bone protection on steroids</td>
<td>Calcium 1000-1200 mg daily; Vitamin D 800-2000 IU daily :: PO :: daily :: Calcium 500-600 mg BID (with food) + Vitamin D 800-2000 IU daily for all patients on chronic steroids</td>
<td>Hypercalcemia, kidney stones</td>
<td>Calcium levels, 25-OH vitamin D</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Bisphosphonate (alendronate)</td>
<td>PO</td>
<td>Osteoporosis prevention on steroids</td>
<td>70 mg weekly :: PO :: weekly :: 70 mg PO weekly if prednisone &gt;7.5 mg for &gt;3 months; take with water, remain upright 30 min</td>
<td>Esophageal disorders, CrCl &lt;35, hypocalcemia</td>
<td>DEXA scan at baseline and q1-2yr; dental exam</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Omeprazole</td>
<td>PO</td>
<td>GI protection on steroids</td>
<td>20 mg daily :: PO :: daily :: 20 mg daily for patients on high-dose steroids or with GI symptoms</td>
<td>Long-term use concerns (Mg, B12, fractures)</td>
<td>Mg levels if prolonged</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Aspirin (low-dose)</td>
<td>PO</td>
<td>Thrombosis prevention with IVIg</td>
<td>81 mg daily :: PO :: daily :: 81 mg daily during IVIg infusions for patients with thrombosis risk factors (age &gt;60, obesity, immobility, prior VTE, hyperviscosity)</td>
<td>Active bleeding, allergy</td>
<td>None routine</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>SC</td>
<td>DVT prophylaxis (immobile patients)</td>
<td>40 mg daily :: SC :: daily :: 40 mg SC daily for immobile hospitalized patients; continue until ambulating</td>
<td>Active bleeding, HIT, CrCl &lt;30</td>
<td>Platelet count</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>PCP prophylaxis (TMP-SMX)</td>
<td>PO</td>
<td>Pneumocystis prevention on high-dose steroids</td>
<td>1 DS tablet 3x/week :: PO :: 3x/week :: TMP-SMX DS (160/800 mg) 3x/week or daily if prednisone &gt;20 mg for &gt;4 weeks + another immunosuppressant</td>
<td>Sulfa allergy (use dapsone or atovaquone)</td>
<td>CBC, renal function</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="4-other-recommendations">4. OTHER RECOMMENDATIONS<a class="headerlink" href="#4-other-recommendations" title="Permanent link">&para;</a></h2>
<h3 id="4a-referrals-consults">4A. Referrals &amp; Consults<a class="headerlink" href="#4a-referrals-consults" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurology consult for diagnosis confirmation, treatment initiation, and long-term management planning</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Neuromuscular specialist referral for diagnostic uncertainty, treatment-refractory cases, or consideration of advanced therapies</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Infusion center referral for ongoing IVIg administration and monitoring</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Home infusion service referral for SCIg training and home therapy setup</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Physical therapy for gait training, fall prevention, strengthening exercises, and mobility optimization</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Occupational therapy for ADL assessment, adaptive equipment, and energy conservation strategies</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Pain management consult for refractory neuropathic pain not responding to gabapentin/pregabalin/duloxetine</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Endocrinology consult for steroid-induced diabetes management or osteoporosis prevention</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Hematology consult if monoclonal protein detected for POEMS or myeloma workup</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Pulmonology consult if respiratory symptoms develop (rare in CIDP; consider GBS overlap)</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">URGENT</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Rheumatology consult if connective tissue disease suspected based on labs or clinical features</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Social work for disability resources, transportation assistance, and community support services</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>PCP follow-up for chronic disease management, steroid side effect monitoring, and preventive care</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<h3 id="4b-patient-instructions">4B. Patient Instructions<a class="headerlink" href="#4b-patient-instructions" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return immediately if progressive weakness, difficulty walking, or breathing problems develop (may indicate disease progression or acute worsening)</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Keep all IVIg/infusion appointments as scheduled to maintain disease control and prevent relapses</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Do not stop immunosuppressive medications suddenly as this may cause disease flare; taper only under physician guidance</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Report signs of infection (fever, cough, dysuria) promptly as immunosuppression increases infection risk</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Use fall precautions including handrails, non-slip surfaces, and assistive devices due to balance and weakness</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>Perform home exercises as prescribed by physical therapy to maintain strength and flexibility</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Monitor for IVIg side effects including headache, fever, chills, or rash during infusions; report severe symptoms</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Keep a symptom diary tracking strength, numbness, and functional abilities to share at follow-up visits</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Carry a medical ID card indicating CIDP diagnosis and current treatments in case of emergency</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Contact GBS-CIDP Foundation (www.gbs-cidp.org) for patient education, support groups, and resources</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<h3 id="4c-lifestyle-prevention">4C. Lifestyle &amp; Prevention<a class="headerlink" href="#4c-lifestyle-prevention" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintain glycemic control (HbA1c &lt;7%) to prevent worsening of neuropathy if diabetic</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Limit alcohol consumption as alcohol worsens peripheral neuropathy and interacts with medications</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Ensure adequate vitamin B12 and folate intake through diet or supplementation to support nerve health</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Avoid smoking as it impairs circulation and may worsen neuropathy</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Stay up to date on vaccinations (flu, pneumonia, COVID-19, shingles) but avoid live vaccines while on immunosuppression</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Wear protective footwear to prevent injury to numb feet and avoid burns or trauma</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Perform daily foot inspections for wounds or ulcers given sensory loss</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Engage in low-impact exercise (swimming, stationary cycling, walking) to maintain cardiovascular health and strength</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Maintain bone health with calcium, vitamin D, and weight-bearing exercise, especially if on steroids</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
<tr>
<td>Manage stress and get adequate sleep as fatigue worsens CIDP symptoms</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
</tr>
</tbody>
</table>
<hr />
<p>‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê
SECTION B: REFERENCE (Expand as Needed)
‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê</p>
<h2 id="5-differential-diagnosis">5. DIFFERENTIAL DIAGNOSIS<a class="headerlink" href="#5-differential-diagnosis" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Alternative Diagnosis</th>
<th>Key Distinguishing Features</th>
<th>Tests to Differentiate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guillain-Barr√© syndrome (GBS)</td>
<td>Acute onset (&lt;4 weeks to nadir); monophasic; often post-infectious</td>
<td>Time course (&lt;8 weeks); NCS; CSF</td>
</tr>
<tr>
<td>Multifocal motor neuropathy (MMN)</td>
<td>Pure motor; asymmetric; conduction block; no sensory involvement</td>
<td>Anti-GM1 antibodies; NCS (conduction block without sensory abnormality)</td>
</tr>
<tr>
<td>POEMS syndrome</td>
<td>Polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes</td>
<td>VEGF, bone survey, SPEP/UPEP (lambda light chain)</td>
</tr>
<tr>
<td>Anti-MAG neuropathy</td>
<td>Distal, sensory-predominant; IgM paraprotein; tremor</td>
<td>Anti-MAG antibody; SPEP/UPEP</td>
</tr>
<tr>
<td>Hereditary neuropathy (CMT)</td>
<td>Family history; pes cavus, hammer toes; slowly progressive since childhood</td>
<td>Genetic testing; NCS pattern</td>
</tr>
<tr>
<td>Diabetic polyneuropathy</td>
<td>Length-dependent sensory &gt; motor; diabetes history</td>
<td>HbA1c; NCS (axonal predominantly)</td>
</tr>
<tr>
<td>Vasculitic neuropathy</td>
<td>Painful; asymmetric; multifocal (mononeuritis multiplex); systemic symptoms</td>
<td>ESR/CRP, ANA, ANCA, nerve biopsy</td>
</tr>
<tr>
<td>Amyloid neuropathy</td>
<td>Autonomic involvement; carpal tunnel; cardiac involvement</td>
<td>Fat pad/nerve biopsy; genetic testing (TTR); serum free light chains</td>
</tr>
<tr>
<td>Lymphoma/paraneoplastic</td>
<td>Weight loss, lymphadenopathy; subacute course</td>
<td>CT/PET; paraneoplastic panel</td>
</tr>
<tr>
<td>Sarcoid neuropathy</td>
<td>Multisystem involvement; skin, lungs, lymph nodes</td>
<td>ACE level; chest imaging; biopsy</td>
</tr>
<tr>
<td>Paraproteinemic neuropathy (other)</td>
<td>IgG or IgA monoclonal; may mimic CIDP</td>
<td>SPEP/UPEP; bone marrow biopsy</td>
</tr>
<tr>
<td>Drug-induced neuropathy</td>
<td>Temporal relationship to drug; axonal pattern</td>
<td>Medication review; NCS</td>
</tr>
<tr>
<td>HIV-associated neuropathy</td>
<td>HIV risk factors; may have CSF pleocytosis</td>
<td>HIV testing; CD4 count</td>
</tr>
<tr>
<td>Lyme neuroborreliosis</td>
<td>Endemic area; facial palsy; radicular pain; CSF pleocytosis</td>
<td>Lyme serology; CSF Lyme antibodies</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="6-monitoring-parameters">6. MONITORING PARAMETERS<a class="headerlink" href="#6-monitoring-parameters" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Frequency</th>
<th>Target/Threshold</th>
<th>Action if Abnormal</th>
<th style="text-align: center;">ED</th>
<th style="text-align: center;">HOSP</th>
<th style="text-align: center;">OPD</th>
<th style="text-align: center;">ICU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical strength exam (MRC grading)</td>
<td>Each visit; q3-6mo stable</td>
<td>Stable or improved</td>
<td>Adjust therapy if declining</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>INCAT disability score</td>
<td>Baseline and q6-12mo</td>
<td>Improvement or stability (0-10 scale)</td>
<td>Consider therapy change if worsening</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>ONLS (Overall Neuropathy Limitations Scale)</td>
<td>Baseline and q6-12mo</td>
<td>Improvement or stability (0-12 scale)</td>
<td>Consider therapy change if worsening</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Grip strength (dynamometer)</td>
<td>Each visit</td>
<td>Stable or improved</td>
<td>Document trend; correlate with symptoms</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Timed 10-meter walk</td>
<td>Baseline and q6-12mo</td>
<td>Stable or improved</td>
<td>Consider PT intensification if slowing</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Nerve conduction studies</td>
<td>Baseline, 6mo after treatment, then annually if stable</td>
<td>Improvement or stability in demyelinating parameters</td>
<td>Guides treatment effectiveness</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Renal function (BUN/Cr)</td>
<td>Before each IVIg; q3-6mo on IVIg</td>
<td>Cr stable (&lt;1.5 or no rise)</td>
<td>Hold IVIg if rising; hydrate; may need dose adjustment</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">STAT</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">STAT</td>
</tr>
<tr>
<td>CBC</td>
<td>q3mo on immunosuppressants</td>
<td>WBC &gt;3K, ANC &gt;1.5K, Hgb &gt;10, Plt &gt;100K</td>
<td>Hold azathioprine/MMF if cytopenic</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>LFTs</td>
<td>q3mo on immunosuppressants</td>
<td>ALT/AST &lt;3x ULN</td>
<td>Hold azathioprine/MMF if significantly elevated</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Blood glucose</td>
<td>Each visit on steroids; HbA1c q3mo</td>
<td>Fasting &lt;126; HbA1c &lt;7%</td>
<td>Intensify diabetes management</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Each visit on steroids</td>
<td>&lt;140/90 (or &lt;130/80 if diabetic)</td>
<td>Initiate antihypertensive if elevated</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>DEXA bone density</td>
<td>Baseline if steroids &gt;3mo; repeat q1-2yr</td>
<td>T-score &gt;-2.5</td>
<td>Bisphosphonate if osteopenia/osteoporosis</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>IgG trough level</td>
<td>q6mo on IVIg/SCIg (optional)</td>
<td>Trough &gt;800-1000 mg/dL</td>
<td>Adjust dose if low and clinically worsening</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">ROUTINE</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>Anti-MAG titer</td>
<td>q6-12mo if positive</td>
<td>Declining with effective therapy</td>
<td>Guides treatment response for anti-MAG</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
<tr>
<td>CD19/CD20 B-cell count</td>
<td>After rituximab q3-6mo</td>
<td>Document depletion and reconstitution</td>
<td>Guides retreatment timing</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">‚Äî</td>
<td style="text-align: center;">EXT</td>
<td style="text-align: center;">‚Äî</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="7-disposition-criteria">7. DISPOSITION CRITERIA<a class="headerlink" href="#7-disposition-criteria" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Disposition</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discharge home</strong></td>
<td>Stable neurological exam; able to ambulate (with assistance if needed); oral medications tolerated; outpatient infusion arranged if needed; follow-up scheduled; adequate social support</td>
</tr>
<tr>
<td><strong>Admit to hospital</strong></td>
<td>Significant new weakness affecting ambulation; need for IV therapy initiation and monitoring; respiratory symptoms (rare but assess); unable to care for self at home</td>
</tr>
<tr>
<td><strong>ICU admission</strong></td>
<td>Respiratory compromise (FVC &lt;30 mL/kg); rapidly progressive weakness raising concern for GBS overlap; severe autonomic dysfunction; hemodynamic instability</td>
</tr>
<tr>
<td><strong>Outpatient infusion center</strong></td>
<td>Stable CIDP on maintenance IVIg; appropriate for regular outpatient infusions every 3-4 weeks</td>
</tr>
<tr>
<td><strong>Home infusion (SCIg)</strong></td>
<td>Stable on IVIg who prefers home therapy; trained in self-injection; appropriate venous access not required</td>
</tr>
<tr>
<td><strong>Rehabilitation facility</strong></td>
<td>Significant residual weakness requiring intensive PT/OT; medically stable; goals for functional improvement</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="8-evidence-references">8. EVIDENCE &amp; REFERENCES<a class="headerlink" href="#8-evidence-references" title="Permanent link">&para;</a></h2>
<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Evidence Level</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>IVIg effective for CIDP</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/18178525/">Hughes et al. Lancet Neurol 2008 (ICE Trial)</a></td>
</tr>
<tr>
<td>IVIg dosing 2 g/kg loading, 1 g/kg maintenance</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/18178525/">Hughes et al. Lancet Neurol 2008 (ICE Trial)</a></td>
</tr>
<tr>
<td>Corticosteroids effective for CIDP</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/29185258/">Hughes et al. Cochrane 2017</a></td>
</tr>
<tr>
<td>Plasma exchange effective for CIDP</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/26378276/">Mehndiratta et al. Cochrane 2015</a></td>
</tr>
<tr>
<td>SCIg non-inferior to IVIg for maintenance</td>
<td>Class I, Level A</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/29288189/">van Schaik et al. Lancet Neurol 2018 (PATH Trial)</a></td>
</tr>
<tr>
<td>EFNS/PNS diagnostic criteria for CIDP</td>
<td>Expert Consensus</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34085743/">Van den Bergh et al. J Peripher Nerv Syst 2021</a></td>
</tr>
<tr>
<td>Rituximab for anti-MAG neuropathy</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/19937997/">Dalakas et al. Ann Neurol 2009</a></td>
</tr>
<tr>
<td>Rituximab for refractory CIDP</td>
<td>Class III, Level C</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/21411742/">Benedetti et al. Neurology 2011</a></td>
</tr>
<tr>
<td>Nodal/paranodal antibodies predict IVIg response</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28566549/">Querol et al. Neurology 2017</a></td>
</tr>
<tr>
<td>Azathioprine as steroid-sparing agent</td>
<td>Class III, Level C</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/29185258/">Hughes et al. Cochrane 2017</a></td>
</tr>
<tr>
<td>Mycophenolate for CIDP</td>
<td>Class III, Level C</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/15477545/">Gorson et al. Neurology 2004</a></td>
</tr>
<tr>
<td>MRI nerve root enhancement supportive criterion</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/34085743/">Van den Bergh et al. J Peripher Nerv Syst 2021</a></td>
</tr>
<tr>
<td>INCAT scale for disability measurement</td>
<td>Expert Consensus</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/11781402/">Merkies et al. Neurology 2002</a></td>
</tr>
<tr>
<td>Treatment-related fluctuations in CIDP</td>
<td>Class II, Level B</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/20021564/">Kuitwaard et al. J Peripher Nerv Syst 2009</a></td>
</tr>
</tbody>
</table>
<hr />
<h2 id="change-log">CHANGE LOG<a class="headerlink" href="#change-log" title="Permanent link">&para;</a></h2>
<p><strong>v1.0 (January 27, 2026)</strong>
- Initial template creation
- Comprehensive diagnostic workup including EFNS/PNS criteria
- First-line treatments: IVIg (loading and maintenance), corticosteroids, PLEX
- Subcutaneous immunoglobulin (SCIg) for home maintenance therapy
- Second-line agents: azathioprine, mycophenolate, rituximab, cyclophosphamide
- Special populations: anti-MAG positive, nodal antibody positive CIDP
- CIDP variants coverage (typical, MADSAM, DADS, sensory, motor)
- Structured dosing format for all medications
- Functional monitoring scales (INCAT, ONLS, grip strength)
- Comprehensive differential diagnosis</p>
<hr />
<h2 id="appendix-a-efnspns-2021-diagnostic-criteria-for-cidp">APPENDIX A: EFNS/PNS 2021 Diagnostic Criteria for CIDP<a class="headerlink" href="#appendix-a-efnspns-2021-diagnostic-criteria-for-cidp" title="Permanent link">&para;</a></h2>
<h3 id="clinical-criteria">Clinical Criteria<a class="headerlink" href="#clinical-criteria" title="Permanent link">&para;</a></h3>
<p><strong>Typical CIDP:</strong>
- Progressive or relapsing symmetric proximal AND distal weakness
- Sensory dysfunction of all four limbs
- Developing over ‚â•8 weeks
- Reduced or absent tendon reflexes in all limbs</p>
<p><strong>Atypical CIDP (at least one of):</strong>
- DADS: Predominantly distal weakness and sensory loss
- MADSAM: Asymmetric weakness (Lewis-Sumner syndrome)
- Focal: Single limb involvement
- Motor: Predominantly motor without sensory involvement
- Sensory: Predominantly sensory without motor involvement</p>
<h3 id="electrodiagnostic-criteria-at-least-1-nerve-meeting-criteria">Electrodiagnostic Criteria (at least 1 nerve meeting criteria)<a class="headerlink" href="#electrodiagnostic-criteria-at-least-1-nerve-meeting-criteria" title="Permanent link">&para;</a></h3>
<p><strong>Motor Nerve Criteria (must meet in ‚â•2 nerves for definite CIDP):</strong></p>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distal motor latency</td>
<td>‚â•50% above ULN</td>
</tr>
<tr>
<td>Motor conduction velocity</td>
<td>‚â§70% below LLN</td>
</tr>
<tr>
<td>F-wave latency</td>
<td>‚â•30% above ULN</td>
</tr>
<tr>
<td>Conduction block</td>
<td>‚â•50% amplitude reduction proximal vs distal</td>
</tr>
<tr>
<td>Temporal dispersion</td>
<td>‚â•30% increase in duration proximal vs distal</td>
</tr>
</tbody>
</table>
<h3 id="supportive-criteria">Supportive Criteria<a class="headerlink" href="#supportive-criteria" title="Permanent link">&para;</a></h3>
<ol>
<li><strong>CSF:</strong> Elevated protein with WBC &lt;10/mm¬≥</li>
<li><strong>MRI:</strong> Enhancement or hypertrophy of nerve roots, brachial or lumbosacral plexus</li>
<li><strong>Objective clinical improvement</strong> with immunomodulatory treatment</li>
<li><strong>Nerve ultrasound:</strong> Increased cross-sectional area of peripheral nerves</li>
<li><strong>Nerve biopsy:</strong> Evidence of demyelination/remyelination</li>
</ol>
<h3 id="diagnostic-categories">Diagnostic Categories<a class="headerlink" href="#diagnostic-categories" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Category</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definite CIDP</strong></td>
<td>Clinical criteria + ‚â•2 nerves meeting electrodiagnostic criteria</td>
</tr>
<tr>
<td><strong>Probable CIDP</strong></td>
<td>Clinical criteria + 1 nerve meeting electrodiagnostic criteria</td>
</tr>
<tr>
<td><strong>Possible CIDP</strong></td>
<td>Clinical criteria but electrodiagnostic criteria not fully met; supportive criteria present</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="appendix-b-incat-disability-scale">APPENDIX B: INCAT Disability Scale<a class="headerlink" href="#appendix-b-incat-disability-scale" title="Permanent link">&para;</a></h2>
<p><strong>Arm Disability Score:</strong>
| Grade | Description |
|-------|-------------|
| 0 | No upper limb problems |
| 1 | Symptoms not affecting function |
| 2 | Symptoms affecting but not preventing function |
| 3 | Symptoms preventing function but able to do some self-care |
| 4 | Symptoms preventing function and most self-care |
| 5 | Cannot use either arm for any purposeful movement |</p>
<p><strong>Leg Disability Score:</strong>
| Grade | Description |
|-------|-------------|
| 0 | Walking not affected |
| 1 | Walking affected but can walk independently outdoors |
| 2 | Uses unilateral support outdoors (cane, crutch, arm) |
| 3 | Uses bilateral support outdoors (two canes, crutches, walker, arm) |
| 4 | Uses wheelchair outdoors; walks with support indoors |
| 5 | Restricted to wheelchair, unable to stand/walk |</p>
<p><strong>Total Score:</strong> Sum of arm + leg scores (0-10)</p>
<hr />
<h2 id="appendix-c-ivig-to-scig-conversion-guide">APPENDIX C: IVIg to SCIg Conversion Guide<a class="headerlink" href="#appendix-c-ivig-to-scig-conversion-guide" title="Permanent link">&para;</a></h2>
<h3 id="conversion-formula">Conversion Formula<a class="headerlink" href="#conversion-formula" title="Permanent link">&para;</a></h3>
<p><strong>Weekly SCIg dose = Monthly IVIg dose √∑ 4</strong></p>
<h3 id="example-conversions">Example Conversions<a class="headerlink" href="#example-conversions" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Monthly IVIg Dose</th>
<th>Weekly SCIg Dose</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 g (0.5 g/kg for 80 kg)</td>
<td>10 g/week</td>
<td>Can divide into 2-3 infusions/week</td>
</tr>
<tr>
<td>60 g (0.75 g/kg for 80 kg)</td>
<td>15 g/week</td>
<td>Can divide into 3-4 infusions/week</td>
</tr>
<tr>
<td>80 g (1 g/kg for 80 kg)</td>
<td>20 g/week</td>
<td>May need 4-7 infusions/week</td>
</tr>
</tbody>
</table>
<h3 id="scig-administration">SCIg Administration<a class="headerlink" href="#scig-administration" title="Permanent link">&para;</a></h3>
<p><strong>Products:</strong>
- Hizentra (20% concentration): Up to 25 mL per site
- Gamunex-C (10% concentration): Up to 30 mL per site</p>
<p><strong>Infusion Sites:</strong>
- Abdomen, thighs, upper arms, hips
- Rotate sites; use 2-4 sites per infusion</p>
<p><strong>Advantages of SCIg:</strong>
- Home administration
- Stable IgG levels (no peaks/troughs)
- Fewer systemic side effects
- Greater independence</p>
<p><strong>Training Required:</strong>
- Initial training by infusion nurse (typically 2-3 sessions)
- Return demonstration of sterile technique
- Recognition of adverse reactions</p>
<hr />
<h2 id="appendix-d-monitoring-timeline">APPENDIX D: Monitoring Timeline<a class="headerlink" href="#appendix-d-monitoring-timeline" title="Permanent link">&para;</a></h2>
<h3 id="first-year-of-treatment">First Year of Treatment<a class="headerlink" href="#first-year-of-treatment" title="Permanent link">&para;</a></h3>
<table>
<thead>
<tr>
<th>Time</th>
<th>Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>NCS/EMG, MRI (if not done), labs (CBC, CMP, HbA1c, SPEP/UPEP, immunoglobulins), INCAT score, grip strength</td>
</tr>
<tr>
<td>2 weeks</td>
<td>If on IVIg: renal function</td>
</tr>
<tr>
<td>4-6 weeks</td>
<td>Clinical assessment; titrate steroids</td>
</tr>
<tr>
<td>3 months</td>
<td>Clinical exam, labs (CBC, CMP, LFTs if on immunosuppressants), HbA1c if on steroids</td>
</tr>
<tr>
<td>6 months</td>
<td>Clinical exam, repeat NCS/EMG, INCAT score, labs</td>
</tr>
<tr>
<td>12 months</td>
<td>Comprehensive review: NCS/EMG, DEXA (if on steroids), INCAT, consider dose reduction trial</td>
</tr>
</tbody>
</table>
<h3 id="maintenance-phase-annual">Maintenance Phase (Annual)<a class="headerlink" href="#maintenance-phase-annual" title="Permanent link">&para;</a></h3>
<ul>
<li>Clinical exam with INCAT/ONLS q6-12 months</li>
<li>NCS/EMG if clinical change</li>
<li>Labs: CBC, CMP, LFTs q3-6 months (based on therapy)</li>
<li>DEXA q1-2 years if on steroids</li>
<li>HbA1c q3-6 months if on steroids or diabetic</li>
<li>Immunoglobulin levels q6-12 months if on IVIg/SCIg</li>
</ul>
<h3 id="dose-reduction-trial">Dose Reduction Trial<a class="headerlink" href="#dose-reduction-trial" title="Permanent link">&para;</a></h3>
<p>Consider after 6-12 months of stable disease:
1. Reduce IVIg by 10-20% or extend interval by 1 week
2. Monitor closely over 4-8 weeks
3. If stable, continue slow reduction
4. If worsening, return to prior effective dose
5. Some patients require lifelong therapy; others may achieve drug-free remission</p>







  
  






                
              </article>
            </div>
          
          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
          <button type="button" class="md-top md-icon" data-md-component="top" hidden>
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M13 20h-2V8l-5.5 5.5-1.42-1.42L12 4.16l7.92 7.92-1.42 1.42L13 8z"/></svg>
  Back to top
</button>
        
      </main>
      
        <footer class="md-footer">
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
        
<div class="md-social">
  
    
    
    
    
      
      
    
    <a href="https://github.com/blondarb/neuro-plans" target="_blank" rel="noopener" title="github.com" class="md-social__link">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--! Font Awesome Free 7.1.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free (Icons: CC BY 4.0, Fonts: SIL OFL 1.1, Code: MIT License) Copyright 2025 Fonticons, Inc.--><path d="M173.9 397.4c0 2-2.3 3.6-5.2 3.6-3.3.3-5.6-1.3-5.6-3.6 0-2 2.3-3.6 5.2-3.6 3-.3 5.6 1.3 5.6 3.6m-31.1-4.5c-.7 2 1.3 4.3 4.3 4.9 2.6 1 5.6 0 6.2-2s-1.3-4.3-4.3-5.2c-2.6-.7-5.5.3-6.2 2.3m44.2-1.7c-2.9.7-4.9 2.6-4.6 4.9.3 2 2.9 3.3 5.9 2.6 2.9-.7 4.9-2.6 4.6-4.6-.3-1.9-3-3.2-5.9-2.9M252.8 8C114.1 8 8 113.3 8 252c0 110.9 69.8 205.8 169.5 239.2 12.8 2.3 17.3-5.6 17.3-12.1 0-6.2-.3-40.4-.3-61.4 0 0-70 15-84.7-29.8 0 0-11.4-29.1-27.8-36.6 0 0-22.9-15.7 1.6-15.4 0 0 24.9 2 38.6 25.8 21.9 38.6 58.6 27.5 72.9 20.9 2.3-16 8.8-27.1 16-33.7-55.9-6.2-112.3-14.3-112.3-110.5 0-27.5 7.6-41.3 23.6-58.9-2.6-6.5-11.1-33.3 2.6-67.9 20.9-6.5 69 27 69 27 20-5.6 41.5-8.5 62.8-8.5s42.8 2.9 62.8 8.5c0 0 48.1-33.6 69-27 13.7 34.7 5.2 61.4 2.6 67.9 16 17.7 25.8 31.5 25.8 58.9 0 96.5-58.9 104.2-114.8 110.5 9.2 7.9 17 22.9 17 46.4 0 33.7-.3 75.4-.3 83.6 0 6.5 4.6 14.4 17.3 12.1C436.2 457.8 504 362.9 504 252 504 113.3 391.5 8 252.8 8M105.2 352.9c-1.3 1-1 3.3.7 5.2 1.6 1.6 3.9 2.3 5.2 1 1.3-1 1-3.3-.7-5.2-1.6-1.6-3.9-2.3-5.2-1m-10.8-8.1c-.7 1.3.3 2.9 2.3 3.9 1.6 1 3.6.7 4.3-.7.7-1.3-.3-2.9-2.3-3.9-2-.6-3.6-.3-4.3.7m32.4 35.6c-1.6 1.3-1 4.3 1.3 6.2 2.3 2.3 5.2 2.6 6.5 1 1.3-1.3.7-4.3-1.3-6.2-2.2-2.3-5.2-2.6-6.5-1m-11.4-14.7c-1.6 1-1.6 3.6 0 5.9s4.3 3.3 5.6 2.3c1.6-1.3 1.6-3.9 0-6.2-1.4-2.3-4-3.3-5.6-2"/></svg>
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    
      
      
      <script id="__config" type="application/json">{"annotate": null, "base": "../..", "features": ["navigation.instant", "navigation.tracking", "navigation.sections", "navigation.expand", "navigation.top", "search.suggest", "search.highlight", "content.code.copy"], "search": "../../assets/javascripts/workers/search.2c215733.min.js", "tags": null, "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}, "version": null}</script>
    
    
      <script src="../../assets/javascripts/bundle.79ae519e.min.js"></script>
      
        <script src="../../assets/js/comments.js"></script>
      
    
  </body>
</html>